Ignite Creation Date:
2025-12-24 @ 1:42 PM
Ignite Modification Date:
2026-01-17 @ 12:40 PM
Study NCT ID:
NCT06511895
Status:
COMPLETED
Last Update Posted:
2025-12-24
First Post:
2024-07-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
Sponsor:
Dizal Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-31
Start Date Type:
ACTUAL
Primary Completion Date:
2025-10-17
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-10-17
Completion Date Type:
ACTUAL
First Submit Date:
2024-07-15
First Submit QC Date:
None
Study First Post Date:
2024-07-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-22
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL